Ascentage Pharma of Suzhou formed a strategic collaboration with Shanghai’s Genor Biopharma that will test a combination of Ascentage’s MDM2-p53 inhibitor and Genor’s anti-PD-1 mAb. MDM2 inhibits the function of p53 through direct protein-protein interaction, Ascentage’s specialty. The two companies will conduct preclinical and clinical studies in both solid tumors and hematologic malignancies. Earlier this year, Ascentage filed for an IPO on the Hong Kong exchange.
Source: China Biotoday
